-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-105 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-105 in T-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in T-Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-118 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-118 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-118 in T-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICG-122 in T-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate...
-
Product Insights
NewT Cell Immunoreceptor With Ig And ITIM Domains – Drugs In Development, 2024
The T Cell Immunoreceptor With Ig And ITIM Domains pipeline drugs market research report outlays comprehensive information on the T Cell Immunoreceptor With Ig And ITIM Domains targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Undisclosed which include indications of Solid Tumor, Non-Small Cell Lung Cancer, and Unspecified. It also reviews key players involved in...
-
Product Insights
NewT Cell Specific Surface Glycoprotein CD28 – Drugs In Development, 2024
The T Cell Specific Surface Glycoprotein CD28 pipeline drugs market research report outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Ophthalmology, and Central Nervous System which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Kidney Transplant Rejection, Graft Versus Host Disease (GVHD), Uveitis,...
-
Innovation Ranking
Innovation Ranking – AT&T Inc
AT&T Inc (AT&T) is a provider of telecommunications, media, and technology services. The company offers wireless communications, data/broadband and internet services, local and long-distance telephone services, telecommunications equipment, managed networking, and wholesale services. AT&T also develops, produces, and distributes feature films, television, gaming, and content in physical and digital formats. It also provides advertisement and entertainment services. The company serves individual customers and business enterprises. It markets services under AT&T, Cricket, SKY, AT&T TV, AT&T PREPAID, AT&T Fiber, and Unefon...
-
Product Insights
NewT Cell Surface Glycoprotein CD3 Epsilon Chain – Drugs In Development, 2024
The T Cell Surface Glycoprotein CD3 Epsilon Chain pipeline drugs market research report outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Central Nervous System which include indications of Follicular Lymphoma, Marginal Zone B-cell Lymphoma, Psoriasis, Rheumatoid Arthritis, Type 1 Diabetes...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD19-CAR-T in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD19-CAR-T in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD19-CAR-T in Lymphoma Drug Details: Gene-modified cell therapy is under development for...